⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Official Title: Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Study ID: NCT02318784

Interventions

Carfilzomib

Study Description

Brief Summary: The purpose of this study is to determine if carfilzomib is safe and effective in the treatment of patients with advanced neuroendocrine tumors.

Detailed Description: Neuroendocrine malignancies such as pancreatic neuroendocrine tumors (PNETs) and gastrointestinal (GI) carcinoids, are generally rare but their incidences are increasing. In vitro and in vivo studies have shown that proteasome inhibitors have activity against a variety of tumor types. Carfilzomib (Kyprolis®) is an irreversible proteasome inhibitor with a favorable safety profile that has been studied in a variety of hematologic and solid tumors. Carfilzomib received accelerated approval from the U.S. FDA in 2012, based on a favorable response rate, for the treatment of patients with multiple myeloma who received at least two prior therapies, and demonstrated disease progression within 60 days of completing the last therapy. In this multi-center study, the investigators propose to evaluate carfilzomib for the treatment of patients with advanced neuroendocrine cancers.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Rocky Mountain Cancer Center, Denver, Colorado, United States

Florida Cancer Specialists, Fort Myers, Florida, United States

Florida Hospital Cancer Institute, Orlando, Florida, United States

Florida Cancer Specialists - North, Saint Petersburg, Florida, United States

Ingalls Cancer Research Center, Harvey, Illinois, United States

Research Medical Center, Kansas City, Missouri, United States

Oncology Hematology Care, INC., Cincinnati, Ohio, United States

Spartanburg Regional Medical Center/Gibbs Cancer Center, Spartanburg, South Carolina, United States

Tennessee Oncology PLLC, Nashville, Tennessee, United States

Center for Cancer and Blood Disorders, Fort Worth, Texas, United States

Contact Details

Name: David Spigel, M.D.

Affiliation: SCRI Development Innovations, LLC

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: